Literature DB >> 16567168

Outcome after surgical resection of recurrent rhabdomyosarcoma.

Andrea Hayes-Jordan1, Debra K Doherty, Sonlee D West, R Beverly Raney, Martin L Blakely, Charles S Cox, Richard J Andrassy, Kevin P Lally.   

Abstract

BACKGROUND/
PURPOSE: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Patients with localized disease have a cure rate of 50% to 90%; however, there has been little evidence that aggressive surgical resection for recurrent disease is of benefit. We reviewed our experience with aggressive surgical resection for recurrent RMS.
METHODS: A retrospective review of the records for patients with RMS was performed. Data extracted included tumor site, histology, initial therapy, time to recurrence, treatment, and outcomes.
RESULTS: From 1991 to 2002, 122 patients with RMS (3 months-18 years) were treated at the MD Anderson Cancer Center. Of 32 patients with recurrent RMS, 19 had surgical resection and 13 had biopsy only or no resection. The common primary sites included extremity (12), genitourinary nonbladder/prostate (7), and retroperitoneal/trunk (7). In the resection group, 33 operations were performed with 5 (15%) major complications and no deaths. Seventeen (52%) of these procedures (7 pelvic, 5 thoracic, 3 amputations, and 2 cranial) were classified as aggressive. After a mean follow-up period of 4.9 years, 7 patients (37%) had no evidence of disease, 8 (42%) died, and 4 were lost to follow-up. There was no correlation between survival and the type of resection. In the no-resection group only, 1 (8%) of 13 patients survived.
CONCLUSIONS: Despite morbidity, aggressive surgical resection is warranted to improve survival in patients with recurrent RMS.

Entities:  

Mesh:

Year:  2006        PMID: 16567168     DOI: 10.1016/j.jpedsurg.2005.12.002

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

1.  Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.

Authors:  Dana L Casey; Yueh-Yun Chi; Sarah S Donaldson; Douglas S Hawkins; Jing Tian; Carola A Arndt; David A Rodeberg; Jonathan C Routh; Timothy B Lautz; Abha A Gupta; Torunn I Yock; Suzanne L Wolden
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

2.  Optimal dosing of cyclophosphamide in rhabdomyosarcoma: It's complicated.

Authors:  John T Lucas; Alberto S Pappo
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

Review 3.  Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects.

Authors:  Deepam Pushpam; Vikas Garg; Sandip Ganguly; Bivas Biswas
Journal:  Onco Targets Ther       Date:  2020-06-08       Impact factor: 4.147

4.  Epitope Detection in Monocytes (EDIM) As a New Method of Liquid Biopsy in Pediatric Rhabdomyosarcoma.

Authors:  Cristian Urla; Matias Julian Stagno; Andreas Schmidt; Rupert Handgretinger; Jörg Fuchs; Steven W Warmann; Evi Schmid
Journal:  Biomedicines       Date:  2022-07-28

5.  A Rare Occurrence of Relapse Malignant Vascular Mesenchymal Tumors (Rhabdomyosarcoma).

Authors:  Pratiksha K Munjewar; Dr Ranjana Sharma; Mayur B Wanjari; Vaishnavi V Kantode
Journal:  Cureus       Date:  2022-07-31

Review 6.  Radioresistance in rhabdomyosarcomas: Much more than a question of dose.

Authors:  Simona Camero; Matteo Cassandri; Silvia Pomella; Luisa Milazzo; Francesca Vulcano; Antonella Porrazzo; Giovanni Barillari; Cinzia Marchese; Silvia Codenotti; Miriam Tomaciello; Rossella Rota; Alessandro Fanzani; Francesca Megiorni; Francesco Marampon
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

7.  Is there a role for salvage re-irradiation in pediatric patients with locoregional recurrent rhabdomyosarcoma? Clinical outcomes from a multi-institutional cohort.

Authors:  Daniel V Wakefield; Bree R Eaton; Austin P H Dove; Chih-Yang Hsu; Thomas E Merchant; Alberto Pappo; Andrew M Davidoff; Natia Esiashvili; Matthew J Krasin; John T Lucas
Journal:  Radiother Oncol       Date:  2018-07-14       Impact factor: 6.280

8.  GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma.

Authors:  S Gallego; D Bernabeu; M Garrido-Pontnou; G Guillen; N Hindi; A Juan-Ribelles; C Márquez; C Mata; J Orcajo; G Ramírez; M Ramos; C Romagosa; D Ruano; P Rubio; R Vergés; C Valverde
Journal:  Clin Transl Oncol       Date:  2021-07-01       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.